These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 25531838

  • 1. Understanding the regulation of pharmaceutical drug promotion [Editorial].
    Krane NA, Sataloff RT.
    Ear Nose Throat J; 2014 Dec; 93(12):486-8. PubMed ID: 25531838
    [No Abstract] [Full Text] [Related]

  • 2. Pharmaceutical promotion to physicians and First Amendment rights.
    Kesselheim AS, Avorn J.
    N Engl J Med; 2008 Apr 17; 358(16):1727-32. PubMed ID: 18420505
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Off-label marketing: free speech or illegal promotion?
    Silverman E.
    BMJ; 2013 Jan 22; 346():f320. PubMed ID: 23341546
    [No Abstract] [Full Text] [Related]

  • 7. Legal and economic perspectives concerning US government investigations of alleged off-label promotion by drug manufacturers.
    Kalb PE, Greenberg PE.
    Pharmacoeconomics; 2009 Jan 22; 27(8):623-5. PubMed ID: 19835018
    [No Abstract] [Full Text] [Related]

  • 8. Higher First Amendment hurdles for public health regulation.
    Outterson K.
    N Engl J Med; 2011 Aug 18; 365(7):e13. PubMed ID: 21812665
    [No Abstract] [Full Text] [Related]

  • 9. Defining "True and Non-Misleading" for Pharmaceutical Promotion.
    Hey SP, Kesselheim AS.
    J Law Med Ethics; 2018 Jun 18; 46(2):552-554. PubMed ID: 30146990
    [No Abstract] [Full Text] [Related]

  • 10. The danger of imperfect regulation: OxyContin use in the United States and Canada.
    Lexchin J, Kohler JC.
    Int J Risk Saf Med; 2011 Jun 18; 23(4):233-40. PubMed ID: 22156088
    [Abstract] [Full Text] [Related]

  • 11. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
    Mello MM, Studdert DM, Brennan TA.
    N Engl J Med; 2009 Apr 09; 360(15):1557-66. PubMed ID: 19357413
    [No Abstract] [Full Text] [Related]

  • 12. Communicating and promoting comparative-effectiveness research findings.
    Neumann PJ.
    N Engl J Med; 2013 Jul 18; 369(3):209-11. PubMed ID: 23863049
    [No Abstract] [Full Text] [Related]

  • 13. Disease-branding and drug-mongering: could pharmaceutical industry promotional practices result in tort liability?
    Cetel JS.
    Seton Hall Law Rev; 2012 Jul 18; 42(2):643-702. PubMed ID: 22708139
    [No Abstract] [Full Text] [Related]

  • 14. FDA warns Bayer about illegally marketing two over the counter products containing aspirin.
    Kmietowicz Z.
    BMJ; 2008 Nov 04; 337():a2402. PubMed ID: 18984638
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Investigating pharmaceutical marketing in Canada using American prosecutions.
    Shoucri R, Persaud N.
    Int J Risk Saf Med; 2014 Nov 04; 26(3):147-53. PubMed ID: 25214160
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.